Back to User profile » Dr Chiara Pavanello
Paper published by Dr Chiara Pavanello:
Review
![Noteworthy comment: The new anti-PCSK9 monoclonal antibodies, with profound abilities to lower LDL-C as well as lipoprotein (a), may be on the verge of ushering in a new era in cardiovascular risk management. This review contains much information about this new class of drugs, and is highly recommended.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Potential of PCSK9 as a new target for the management of LDL cholesterol
Mombelli G, Castelnuovo S, Pavanello C
Research Reports in Clinical Cardiology 2015, 6:73-86
Published Date: 15 July 2015